Nevro Corp.

DB:1N7 Stock Report

Market Cap: €134.9m

Nevro Valuation

Is 1N7 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 1N7 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate 1N7's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate 1N7's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 1N7?

Key metric: As 1N7 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for 1N7. This is calculated by dividing 1N7's market cap by their current revenue.
What is 1N7's PS Ratio?
PS Ratio0.3x
SalesUS$419.15m
Market CapUS$139.02m

Price to Sales Ratio vs Peers

How does 1N7's PS Ratio compare to its peers?

The above table shows the PS ratio for 1N7 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average2.2x
PUS PULSION Medical Systems
3.7xn/a€131.9m
SBS Stratec
1.4x7.4%€361.6m
DRW3 Drägerwerk KGaA
0.3x3.8%€785.0m
EUZ Eckert & Ziegler
3.2x5.4%€900.9m
1N7 Nevro
0.3x3.3%€139.0m

Price-To-Sales vs Peers: 1N7 is good value based on its Price-To-Sales Ratio (0.3x) compared to the peer average (2.2x).

Price to Sales Ratio vs Industry

How does 1N7's PS Ratio compare vs other companies in the DE Medical Equipment Industry?

5 CompaniesPrice / SalesEstimated GrowthMarket Cap
Industry Avg.3.6x5.8%
1N7 Nevro
 0.3x3.3%US$139.02m
DRW3 Drägerwerk KGaA
0.3x3.8%US$808.94m
PHH2 Paul Hartmann
0.3xn/aUS$808.88m
1N7 0.3xIndustry Avg. 3.6xNo. of Companies4PS01.63.24.86.48+
5 CompaniesEstimated GrowthMarket Cap
Industry Avg.3.6x14.1%
1N7 Nevro
 0.3x5.0%US$139.02m
No more companies

Price-To-Sales vs Industry: 1N7 is good value based on its Price-To-Sales Ratio (0.3x) compared to the European Medical Equipment industry average (3.6x).

Price to Sales Ratio vs Fair Ratio

What is 1N7's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

1N7 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio0.3x
Fair PS Ratio1.2x

Price-To-Sales vs Fair Ratio: 1N7 is good value based on its Price-To-Sales Ratio (0.3x) compared to the estimated Fair Price-To-Sales Ratio (1.2x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 1N7 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€3.54
€5.48
+54.9%
41.8%€12.54€3.86n/a12
Dec ’25€4.28
€6.64
+55.0%
32.9%€12.24€3.77n/a11
Nov ’25€4.84
€6.64
+37.2%
31.7%€11.94€3.67n/a11
Oct ’25€4.92
€6.86
+39.4%
29.3%€11.74€3.61n/a11
Sep ’25€5.65
€6.78
+20.0%
29.0%€11.76€3.62n/a12
Aug ’25€9.10
€12.92
+42.0%
53.6%€36.69€7.52n/a14
Jul ’25€7.80
€13.68
+75.3%
47.9%€36.96€8.32n/a15
Jun ’25€8.40
€13.68
+62.8%
47.9%€36.96€8.32n/a15
May ’25€10.60
€16.62
+56.8%
35.2%€37.49€13.12n/a15
Apr ’25€13.20
€17.93
+35.8%
30.1%€36.96€12.94n/a15
Mar ’25€13.40
€17.93
+33.8%
30.1%€36.96€12.94n/a15
Feb ’25€15.20
€19.75
+29.9%
30.5%€36.85€13.82n/a16
Jan ’25€19.80
€19.34
-2.3%
32.9%€36.36€11.82€3.5016
Dec ’24€15.80
€18.74
+18.6%
38.2%€37.30€12.12€4.2816
Nov ’24€13.60
€24.33
+78.9%
40.1%€54.11€16.14€4.8415
Oct ’24€18.50
€26.18
+41.5%
33.4%€52.55€17.52€4.9215
Sep ’24€18.40
€26.18
+42.3%
33.4%€52.55€17.52€5.6515
Aug ’24€22.60
€32.02
+41.7%
41.0%€66.96€21.43€9.1015
Jul ’24€23.40
€34.42
+47.1%
39.3%€68.72€21.99€7.8014
Jun ’24€25.60
€38.43
+50.1%
35.4%€71.11€27.14€8.4014
May ’24€27.40
€38.87
+41.9%
35.0%€68.97€28.13€10.6012
Apr ’24€32.60
€42.37
+30.0%
31.1%€70.76€31.13€13.2011
Mar ’24€29.60
€42.37
+43.1%
31.1%€70.76€31.13€13.4011
Feb ’24€33.60
€41.16
+22.5%
28.6%€68.87€30.30€15.2011
Jan ’24€37.20
€45.21
+21.5%
26.5%€70.64€29.20€19.8011

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/05 09:02
End of Day Share Price 2025/01/03 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Nevro Corp. is covered by 26 analysts. 16 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
David RescottBaird
null nullBaird
Michael PolarkBaird